Skip to main content

Table 2 Clinicopathologic Features of 119 HPV16-Positive Squamous Cell Carcinoma Cases with European Variants

From: HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer

TRAIT

CATEGORY

16-EP (%1)

n = 52

16-EV (%1)

n = 20

16-EV-G (%1)

n = 47

Total (%2)

n = 119

P-VALUE3

 

Non-keratinizing

26 (41.9)

12 (19.4)

24 (38.7)

62 (57.4)

 

CELL TYPE

Keratinizing

21 (45.7)

5 (10.9)

20 (43.5)

46 (42.6)

0.53

 

Squamous, NOS4

5 -

3 -

3 -

11 -

 

AGE GROUP

20-40

15 (37.5)

5 (12.5)

20 (50.0)

40 (33.6)

 
 

41-50

20 (45.5)

11 (25.0)

13 (29.5)

44 (37.0)

0.26

 

51-72

17 (48.6)

4 (11.4)

14 (40.0)

35 (29.4)

 

RACE

White

44 (45.8

15 (15.6)

35 (38.5)

94 (76.1)

 
 

Black

2 (50.0)

2 (50.0)

0

4 (3.4)

0.07

 

Hispanic

2 (28.6)

0

5 (71.4)

7 (5.9)

 
 

Native American

3 (30.0)

1 (10.0)

6 (60.0)

10 (8.5)

 
 

Asian

1 (50.0)

1 (50.0)

0

2 (1.7)

 
 

Other

0 -

1 (100)

0

1 (0.8)

 
 

ND5

0 -

0 -

1 -

1 -

 
 

1A

6 (42.9)

2 (14.3)

6 (42.9)

14 (12.2)

 

STAGE (FIGO)

1B1

16 (44.4)

8 (22.2)

12 (33.3)

36 (31.3)

0.75

 

1B2

4 (28.6)

3 (21.4)

7 (50.0)

14 (12.2)

 
 

2

10 (45.5)

1 (4.5)

11 (50.0)

22 (19.1)

 
 

3

9 (50.0)

3 (16.7)

6 (33.3)

18 (15.6)

 
 

4

5 (45.5)

3 (27.3)

3 (27.3)

11 (9.6)

 
 

Recurrent/Unstaged

2 -

0 -

2 -

4 -

 
 

0

4 (80.0)

0 -

1 (20.0

5 (4.3)

 

GRAVIDITY

1-3

24 (35.8)

11 (16.4)

32 (47.8)

67 (57.8)

0.18

 

>3

22 (50.0)

9 (20.5)

13 (29.5)

44 (37.9)

 
 

ND5

2 -

0 -

1 -

3 -

 

PARAMETRIA6

Negative

20 (43.5)

8 (17.4)

18 (39.1)

46 (53.5)

 
 

Positive

19 (47.5)

6 (15.0)

15 (37.5)

40 (46.6)

0.92

 

ND

13 -

6 -

14 -

33 -

 

Table 2 (cont'd)

      
 

<1

6 (40.0)

2 (13.3)

7 (46.7)

15 (14.7)

 

TUMOR SIZE6 (cm)

1-4

18 (46.2)

7 (17.9)

14 (35.9)

39 (38.2)

0.96

 

>4

21 (43.8)

7 (14.6)

20 (41.7)

48 (47.1)

 
 

ND

7 -

4 -

6 -

17 -

 
 

< 3

3 (23.1)

2 (15.4)

8 (61.5)

13 (22.0)

 

INVASION DEPTH 7

3.1 - 5.0

5 (62.5)

0

3 (37.5)

8 (13.3)

0.24

(mm)

>5

19 (50.0)

7 (18.4)

12 (31.6)

38 (64.4)

 
 

ND

25 -

11 -

24 -

60 -

 
 

Positive

15 (40.5)

6 (16.2)

16 (43.2)

37 (59.7)

 

VSI7

Negative

12 (48.0)

3 (12.0)

10 (40.0)

25 (40.3)

0.83

 

ND

25 -

11 -

21 -

57 -

 

RESECTION

Positive

7 (63.6)

1 (9.1)

3 (27.3)

11 (19.3)

 

MARGINS7

Negative

19 (41.3)

8 (17.4)

19 (41.3)

46 (80.7)

0.49

 

ND

26 -

11 -

25 -

65 -

 
 

Negative

20 (47.6)

4 (9.5)

18 (42.9)

42 (49.4)

 

LN STATUS8

Positive

18 (41.9)

8 (18.6)

17 (39.5)

43 (50.6)

0.55

 

ND

14 -

8 -

12 -

34 -

 
 

NED

34 42.5)

13 (16.3)

33 (41.3)

80 (67.2)

 

STATUS9

DOD

18 46.2)

7 (17.9)

14 (35.9)

39 (32.8)

0.87

  1. 1: Percentage calculated across.
  2. 2: Percentage calculated down.
  3. 3: Fisher's exact test
  4. 4: Squamous, NOS: Women with very small tumors or tiny biopsies were difficult categorize as to cell type and were not included in these analyses.
  5. 5: ND: No data available
  6. 6: Tumor size and parametrial assessment were determined by pathologic evaluation of a radical hysterectomy or as part of a clinical staging procedure.
  7. 7: Depth of invasion, margin status and status of vascular space invasion were available only for women with early stage tumors who had a conization or hysterectomy.
  8. 8: Lymph node dissections were routinely performed as part of radical hysterectomy. It is not standard for higher stage women although cervical biopsy with lymph node dissection was performed for some higher stage women.
  9. 9: Status: NED = No evidence of cervical cancer; DOD = Dead of cervical cancer
Back to article page